AstraZeneca PLC (Mexico) Today
| AZNN Stock | MXN 1,384 6.50 0.47% |
Performance0 of 100
| Odds Of DistressLess than 44
|
AstraZeneca PLC is trading at 1383.50 as of the 28th of November 2024; that is 0.47 percent decrease since the beginning of the trading day. The stock's open price was 1390.0. AstraZeneca PLC has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for AstraZeneca PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company has 3.1 B outstanding shares. More on AstraZeneca PLC
Moving against AstraZeneca Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
AstraZeneca Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AstraZeneca PLC's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AstraZeneca PLC or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Pascal Soriot |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
AstraZeneca PLC (AZNN) is traded on Mexican Exchange in Mexico and employs 48 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 4.04 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AstraZeneca PLC operates under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 3.1 B outstanding shares.
AstraZeneca PLC has accumulated about 15.63 B in cash with 9.81 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.96.
Check AstraZeneca PLC Probability Of Bankruptcy
Ownership AllocationAstraZeneca PLC holds a total of 3.1 Billion outstanding shares. Almost 82.02 percent of AstraZeneca PLC outstanding shares are held by general public with 0.04 (percent) owned by insiders and only 17.94 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check AstraZeneca Ownership Details
AstraZeneca PLC Risk Profiles
Although AstraZeneca PLC's alpha and beta are two of the key measurements used to evaluate AstraZeneca PLC's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.25 | |||
| Standard Deviation | 2.38 | |||
| Variance | 5.65 | |||
| Risk Adjusted Performance | (0.07) |
AstraZeneca Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in AstraZeneca PLC without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
AstraZeneca PLC Corporate Directors
| Marc Dunoyer | Chief Financial Officer, Executive Director | Profile | |
| Sherilyn McCoy | Non-Executive Independent Director | Profile | |
| Genevieve Berger | Non-Executive Independent Director | Profile | |
| Nazneen Rahman | Non-Executive Independent Director | Profile |
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.